Over the past 12‑18 months the Monkeypox Therapeutics market has accelerated, driven by a cascade of strategic moves and regulatory shifts. In March 2023, Gilead Sciences partnered with MiroBio to co‑develop an oral antiviral, leveraging Gilead’s nucleotide platform. The same year, ViroGen acquired CureTech for $210 million, adding a late‑stage monoclonal antibody pipeline to its portfolio. In September 2023, Novartis launched NVT‑101, the first orally bioavailable small‑molecule indicated for post‑exposure prophylaxis, and secured fast‑track status from the FDA. The European Medicines Agency (EMA) updated its orphan‑drug guidance in February 2024, shortening the review timeline for Monkeypox agents. Meanwhile, venture capital inflow surged, with a $120 million Series C round led by Sequoia Capital to expand manufacturing capacity in Singapore. These developments shape the current Monkeypox Therapeutics industry trends, signalling a shift toward outpatient‑focused, scalable solutions and heightened cross‑border collaborations. In early 2024 the U.S. CDC revised its treatment guidelines, endorsing home‑based dosing regimens and expanding insurance reimbursement, which has accelerated demand among community health providers. Additionally, several biotech firms announced joint ventures to develop next‑generation CRISPR‑based therapies, underscoring a move toward precision medicine.
